Breaks Categories: News

ThursdayAug 15, 2024 2:40 pm

NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Announces Completion of Name Change, Begins Trading Under New Symbol

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), formerly FSD Pharma Inc., a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has finalized its previously announced name change and consolidation. According to the announcement, the company’s class B subordinate voting shares began trading today under the new ticker symbol QNTM. In addition, the company closed on a nonbrokered private placement and issued four postconsolidation Class A multiple voting shares for $18 per share, resulting in gross proceeds of $72. Xorax Family Trust, a trust of which Quantum BioPharma CEO and cochair Zeeshan Saeed is a beneficiary,…

Continue Reading

ThursdayAug 15, 2024 1:51 pm

NetworkNewsBreaks – Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF), American West Metals Report ‘Excellent Results’ from Ongoing Drilling at Storm Project

Aston Bay (TSX.V: BAY) (OTCQB: ATBHF), a mineral exploration company exploring for high-grade critical and precious metal deposits in Nunavut, Canada, and Virginia, USA, and American West Metals Limited today provided an update on drilling activities at the Storm Copper Project on Somerset Island, Nunavut. According to the update, the resource delineation program is on track with multiple high-grade copper intervals confirmed by assays at the Cyclone and Chinook Deposits. Additionally, the drill program continues to achieve milestones; a total of 100 Reverse Circulation (“RC”) drill holes and 12 diamond drill holes totaling over 15,500 meters have been completed at…

Continue Reading

ThursdayAug 15, 2024 1:47 pm

NetworkNewsBreaks – Actuate Therapeutics, Inc. (NASDAQ: ACTU) Closes on $22.4M Initial Public Offering

Actuate Therapeutics (NASDAQ: ACTU), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers, recently announced the closing of its previously announced initial offering. The offering comprised 2,800,000 shares of the company’s common stock at a price of $8.00 per unit to the public, raising a total of $22,400,000 in gross proceeds before deductions. In addition, the company has granted a 30-day option to the underwriters to purchase up to 420,000 additional shares, representing 15% of the shares sold in the offering, solely to cover over-allotments, if any, at the initial…

Continue Reading

ThursdayAug 15, 2024 1:30 pm

NetworkNewsBreaks – Software Effective Solutions Corp. (SFWJ) to Eliminate $450,000 of Convertible Debt by the End of Q3

Software Effective Solutions (OTC: SFWJ) (d/b/a MedCana), a holding company focused on the cannabis and agricultural technology sectors, today announced that all convertible debt on its balance sheet amounting to $450,000 will be eliminated by the end of the third quarter. “Our goal is to build a strong company focusing on revenue and, most importantly, enhanced shareholder value. We want our shareholders to invest with confidence, knowing they will not have to worry about any debt conversion hindering the value of their shares,” said Gabriel Diaz, CEO of MedCana. To view the full article, visit https://nnw.fm/Tx8Ay About Software Effective Solutions…

Continue Reading

ThursdayAug 15, 2024 12:29 pm

NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Releases Q2 2024 Financial Report, Operational Update

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, is reporting on financial and operations results for its second quarter 2024, the period that ended June 30, 2024. Highlights of the report include steady progress made toward key clinical and regulatory milestones on its HeartBeam AIMIGo(TM) System, including the 510(k) submission to the U.S. Food and Drug Administration (FDA); the report also noted that the company has completed two presubmission meetings with the FDA regarding the company’s planned 510(k) submission of its 12-lead synthesis software. “The second quarter of 2024 was…

Continue Reading

ThursdayAug 15, 2024 12:05 pm

NetworkNewsBreaks – Golden Triangle Ventures Inc. (GTVH), Saxon Capital Group Partner to Bring ‘Groundbreaking’ Solar Glass Technology to Destino Ranch

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, today announced a strategic partnership with Saxon Capital Group Inc. (OTC: SCGX). As part of the partnership, SCGX will utilize and integrate its revolutionary Energy Glass Solar(TM) technology across the entirety of GTVH’s highly anticipated Destino Ranch project. Energy Glass Solar(TM) is a patented, optically clear photovoltaic window system that generates continuous electricity from sunlight, diffused, and ambient light. It is an ideal solution for Destino Ranch, offering numerous advantages. “We are thrilled to partner with Saxon Capital Group to bring their groundbreaking solar glass technology to Destino Ranch. This partnership…

Continue Reading

ThursdayAug 15, 2024 11:51 am

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Publishes Q2 2024 Results

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today released its financial results for the second quarter ended June 30, 2024 (“Q2 2024”). The company also discussed the clinical development progress of Berubicin, its lead program, and TPI 287, its recently in-licensed abeotaxane for the treatment of brain malignancies. CNS Pharmaceutical expects to be able to release final topline data from its potentially pivotal trial of Berubicin in the first half of 2025. The trial is evaluating Berubicin in adult patients with…

Continue Reading

ThursdayAug 15, 2024 11:32 am

NetworkNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Reports on Voting Results of 2024 Annual and Special Meeting of Shareholders

Flora Growth (NASDAQ: FLGC), a consumer-packaged goods leader and pharmaceutical distributor, is reporting on its 2024 Annual and Special Meeting of Shareholders. The meeting. According to the announcement, shareholders voted on and approved all five proposals on the agenda. Proposals included the election of four directors to the company’s board of directors; the reappointment of Davidson & Company LLP, an independent registered public accounting firm, as the company auditors; amending FLGC’s Incentive Compensation Plan to increase the issuable number of shares; granting stock appreciation rights to the company's CEO and CFO; and issuing 635,363 shares in accordance with NASDAQ guidelines…

Continue Reading

ThursdayAug 15, 2024 11:03 am

NetworkNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Q2 2024 Financial Results, Shares Business Update

Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit. The company today published its financial results for the second quarter ended June 30, 2024, and provided a business update. Scinai plans to host a webinar to discuss its Q2 2024 results and business update on August 20, 2024, at 11 a.m. EDT/6 p.m. Israel Time. Recent highlights from Q2 2024 included the signing of an agreement to restructure a $29 million bank loan to equity and plans to regain Nasdaq compliance by…

Continue Reading

ThursdayAug 15, 2024 9:52 am

NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Q2 2024 Financial Results, Provides Update Showing ‘Productive’ Recent Months

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today released financial results for its second quarter ended June 30, 2024, and provided a business update. According to the update, results from the company’s completed Phase 2/3 AD study showed that buntanetap significantly improved cognition in patients with early AD. Additionally, data from its Phase 3 PD study revealed that buntanetap led to improvements in both the Unified Parkinson’s Disease Rating Scale (“MDS-UPDRS”) and cognition across several PD subpopulations. The company also discussed the filing of patents, team…

Continue Reading